Author

Joanne Xiu

Observed name: J. Xiu

Institution: Caris Life Sciences (United States)

Observed institution: Caris Life Sciences (United States)

OpenAlex ID: A5087103669

Genomic landscape, immune microenvironment and survival in male versus female breast cancer

2026 · D. Trapani, S.K. Deshmukh, et al. · ESMO Open · 2

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers

2026 · A. Shreenivas, A. Elliott, et al. · ESMO Open · 1

CXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancer

2026 · Sepideh Gholami, Anwaar Saeed, et al. · BMJ Oncology · 1

P2.097: Prevalence and Spectrum of Germline Variants in Non-Small Cell Lung Cancer: Insights From a Large-Scale CARIS Analysis

2026 · N. Choradia, W. Gu, et al. · Journal of Thoracic Oncology

Association of ESR1 amplification with survival and benefit from CDK4/6 inhibition in breast cancer.

2026 · George W. Sledge, Joanne Xiu, et al. · Journal of Clinical Oncology

31P ERBB2 Mutations in Metastatic Breast Cancer: Histology-Specific Molecular, Immune, and Clonal Features

2026 · G. Nader Marta, S.K. Deshmukh, et al. · ESMO Open

Abstract PS4-01-13: Comparative efficacy of antibody drug conjugates (ADCs) in male versus female breast cancer across the spectrum of HER2 expression

2026 · D. Trapani, S. Deshmukh, et al. · Clinical Cancer Research

Abstract PS2-09-08: Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database

2026 · S. Chumsri, S. Deshmukh, et al. · Clinical Cancer Research

Abstract PS2-08-02: Comprehensive Characterization of PTEN loss by IHC and PTEN alteration by NGS in Metastatic HR-Positive, HER2-Negative Breast Cancer-- An Exploratory Analysis of Biomarker Concordance and Co-Occurrence

2026 · R. L. Mahtani, S. C. Smith, et al. · Clinical Cancer Research

P2.06.52 Survival and Mutational Differences of GPER and Estrogen Receptor (ER) in NSCLC

2025 · R. Hsu, S. Wu, et al. · Journal of Thoracic Oncology

1052P Comprehensive molecular profiling of squamous non-small cell lung cancer by smoking status

2022 · J. Reuss, N. Gandhi, et al. · Annals of Oncology

105P Pan-tumor survey of ROS1 fusions detected by next-generation RNA sequencing

2022 · S. Zhang, M. Nagasaka, et al. · Annals of Oncology

72P Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET+ colorectal carcinoma as a unique molecular subset of CRC

2022 · M. Nagasaka, D. Brazel, et al. · Annals of Oncology

MA05.08 MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History

2022 · J. Marks, J. Yin, et al. · Journal of Thoracic Oncology

Works count: 14

Citation count: 4

H-index: 1

I10-index: